Biotechnology Value Fund’s Investments Highlighted

Firm News

Elsevier’s In Vivo Blog recently featured Olshan's client, Biotechnology Value Fund in an article about the Fund’s investments in various pharmaceutical related companies including Addex Pharmaceuticals, a Swiss pharmaceuticals company; Celera Corporation, a diagnostics company focused on genetic sequencing and Facet Biotech which is focused on oncology therapeutics. The article also discusses the Fund’s recent involvement with Avigen, Inc. and the Fund’s role in successfully merging Avigen with MediciNova, Inc.

Olshan represented Biotechnology Value Fund in these transactions.

Media Contact

Marketing Contact
Mizi Mehaj
Marketing & Administrative Manager

Jump to Page

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.